-transparent.png){kind=logo}
During a one week period patients with liver cirrhosis and a control group were treated with a repeated dosage of the new heart glcoside Meproscillarin. After achieving a steady state in plasma level the same Meproscillarin plasma levels were found among both groups. Compared with the control group no difference was detected in the elimination rate of Meproscillarin in patients with liver cirrhosis, which means a complex disturbed liver function. Nevertheless the greater variance of the Meproscillarin plasma levels in the patients with liver cirrhosis in comparison with the controls means a diminished predictability of the therapeutic success in the cirrhosis group. With this limitation Meproscillarin can be used therapeutically in patients with liver cirrhosis, because a toxic accumulation is not to be expected.
K Burkert, and
H Beckmann
January 1978,
Arzneimittel-Forschung,
K Burkert, and
H Beckmann
January 1978,
Arzneimittel-Forschung,
K Burkert, and
H Beckmann
January 1978,
Arzneimittel-Forschung,
K Burkert, and
H Beckmann
April 1976,
Praktische Anasthesie, Wiederbelebung und Intensivtherapie,
K Burkert, and
H Beckmann
January 1978,
Arzneimittel-Forschung,
K Burkert, and
H Beckmann
January 2002,
Acta poloniae pharmaceutica,
K Burkert, and
H Beckmann
October 1977,
Thrombosis and haemostasis,
K Burkert, and
H Beckmann
January 1978,
Arzneimittel-Forschung,
K Burkert, and
H Beckmann
January 1975,
Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
K Burkert, and
H Beckmann
June 1972,
Bollettino chimico farmaceutico,
